Episode
Pandemic good news
- Podcast
- Dr. John Campbell
- Published
- Jul 22, 2026
- Duration seconds
- 745
- Processing state
not_requested- Canonical source
- https://traffic.megaphone.fm/VG8155022646.mp3
Actions
POST https://stenobird.com/v1/public/podcasts/dr-john-campbell-7851784/episodes/pandemic-good-news/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/dr-john-campbell-7851784/pandemic-good-news.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
CDC variant report https://covid.cdc.gov/covid-data-tracker/#variant-proportions Some increase in BA.4.6 and BA.2.75 BA.4.6 Progressive US increase, starting to slowly displace BA.5 US of America (9,526) Canada (1,007) Denmark (500) France (400) Australia (288) Germany (248) Chile (242) Dominican Republic (173), Peru (149), Luxembourg (123), Belgium (102), Israel (101), Italy (94), Ireland (93), Sweden (92), Spain (85), Netherlands (84), Brazil (76), Argentina (68), Japan (67), New Zealand (60), Switzerland (54), Puerto Rico (53), South Africa (53), Ecuador (49), Mexico (35), Colombia (34), Trinidad and Tobago (30), Czech Republic (27), Costa Rica (23), Jamaica (21), Portugal (20), South Korea (19), Austria (17), Botswana (17), Indonesia (13), Sint Maarten (12), Senegal (11) BA.2.75 Some US increase Growth rate is currently 61% per week relative to co-circulating lineages Current US nowcast BA.5 84.8% (UK, 87.2%) BA.4.6 10.3% (UK, 3.3) BA.4 1.8% BF.7 1.7% BA.2.75 1.3% (UK, 1.6%) BA.2 0% (UK, 0.5%) BA.1s 0% Delta 0% Others 0% (UK, 2.4%) XE 0% UK, technical briefing 45 (September 2022) https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1103869/Technical-Briefing-45-9September2022.pdf Contains early data and analysis on emerging variants Findings have a high level of uncertainty Data cut-off of 5 September 2022 BA.5 BA.5 is the predominant circulating variant in the United Kingdom Newly designated variant – V-22SEP-01 (BA.4.6) Omicron sub-lineage BA.4.6 An apparent small growth advantage relative to BA.5. BA.4.6 represented 3.31% of UK samples Preliminary neutralisation data from BA.4.6 Expect some immune escape from BA.4 or BA.5 antibodies There is NO increased risk of hospital admission after BA.4 or BA.5 infection compared t…